Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Repositioning Immunotherapy in VetArans With Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BND-35 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
- Status
- RECRUITING
- Phase
- PHASE2
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Status
- RECRUITING
- Phase
- PHASE2
Drug Screening Using IMD in Bladder Cancer
- Status
- ENROLLING_BY_INVITATION
- Phase
- EARLY_PHASE1
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Status
- TERMINATED
- Phase
- PHASE1
Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
- Status
- COMPLETED
- Phase
- N/A
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
- Status
- RECRUITING
- Phase
- PHASE4
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Status
- RECRUITING
- Phase
- PHASE3